Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 75893-75-3 | MDL No. : | MFCD18255573 |
Formula : | C9H9NO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | AZQLYGCISPLJER-UHFFFAOYSA-N |
M.W : | 163.17 g/mol | Pubchem ID : | 12440058 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.33 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 43.66 |
TPSA : | 50.19 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.62 cm/s |
Log Po/w (iLOGP) : | 1.44 |
Log Po/w (XLOGP3) : | 0.95 |
Log Po/w (WLOGP) : | 1.59 |
Log Po/w (MLOGP) : | -0.13 |
Log Po/w (SILICOS-IT) : | 1.75 |
Consensus Log Po/w : | 1.12 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -1.69 |
Solubility : | 3.35 mg/ml ; 0.0205 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.59 |
Solubility : | 4.18 mg/ml ; 0.0256 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.99 |
Solubility : | 1.68 mg/ml ; 0.0103 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.55 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With water; sodium hydroxide; In ethanol; for 20.0h;Reflux; | General procedure: Intermediate 6A: 5-Iso ropyl-3-methyI-lH-pyrazole-4-carboxylic acidEthyl 5-isopropyl-3-methyl-lH-pyrazole-4-carboxylate (WO2009/013211) (2.1 g, 10.7 mmol) was dissolved in ethanohwater (2:1, 10 mL), to it was added sodium hydroxide (857 mg, 21.4 mmol) and refluxed for 20 h. Volatiles were evaporated under reduced pressure. Aqueous layer was diluted with water (20 mL) and extracted with ethyl acetate (2 X 20 mL). Combined organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 750 mg (73%) of 5 -isopropyl-3 -methyl- 1H- pyrazole-4-carboxylic acid.? NMR (400 MHz, CDCI3): delta 1.17 (d, J = 6.9 Hz, 6H), 2.32 (s, 3H), 3.45-3.54 (m, 1H), 12.23 (brs, 2H). MS (ES) m/z 169.1 (M+l). | |
With sodium hydroxide; In ethanol; water; for 20.0h;Reflux; | General procedure: Intermediate 6A: 5-Isopropyl-3-methyl-1H-pyrazole-4-carboxylic acid Ethyl 5-isopropyl-3-methyl-1H-pyrazole-4-carboxylate (WO2009/013211) (2.1 g, 10.7 mmol) was dissolved in ethanol:water (2:1, 10 mL), to it was added sodium hydroxide (857 mg, 21.4 mmol) and refluxed for 20 h. Volatiles were evaporated under reduced pressure. Aqueous layer was diluted with water (20 mL) and extracted with ethyl acetate (2*20 mL). Combined organic layer was washed with brine (25 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give 750 mg (73%) of 5-isopropyl-3-methyl-1H-pyrazole-4-carboxylic acid. 1H NMR (400 MHz, CDCl3): delta 1.17 (d, J=6.9 Hz, 6H), 2.32 (s, 3H), 3.45-3.54 (m, 1H), 12.23 (brs, 2H). MS (ES) m/z 169.1 (M+1). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
35% | With 4-methyl-morpholine; benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20.0℃; for 16.0h; | Step-6: Synthesis of N-[3-bromo-2-[[tert-butyI(dimethyl)siIyl]oxymethyl]phenyl]-6- cyclopropyl-pyridine-3-carboxamide: To a solution of <strong>[75893-75-3]6-cyclopropylpyridine-3-carboxylic acid</strong> (0.5 g, 3.06 mmol), 3-bromo-2-[[tert- butyl(dimethyl)silyl]oxymethyl]aniline (1.16 g, 3.67 mmol) and HOBt (0.495 g, 3.67 mmol) in DCM (15 mL) was added NMM (0.5 mL, 4-59 mmol) and EDCI.HCl (0.876 g, 4.59 mmol). The reaction mixture was stirred at room temperature for 16 h. After completion of the reaction (as indicated by TLC), water (10 mL) was added to it and extraction was carried out using DCM (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2S04, filtered and concentrated under reduced pressure. The residue was purified using column chromatography (Si02, 10% ethyl acetate in hexanes) to afford title compound (0.5 g, 35%). LCMS: m/z 461.2 (M + 1)+. NMR (400 MHz, CDC13) delta 0.15 (s, 6H), 0.87 (s, 9H), 1.05-1.10 (m, 2H), 1.1 1-1.51 (m, 2H), 2.06-2.16 (m, 1H), 5.1 1 (s, 2H), 7.19-7.23 (aromatics, 2H), 7.33 (d, J = 8.0 Hz, 1H), 8.03 (dd, J = 8.0, 2.0 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H), 8.99 (d, J = 2.0 Hz, lH), 9.99 (s, lH). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
13% | With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; at 20.0℃; for 16.0h;Inert atmosphere; | Example 56 6-Cyclopropyl-N-([2-fluoro-4-[2-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]phenyl]methyl)pyridine-3-carboxamide (56) In a 10-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, [2-fluoro-4-[2-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]phenyl]methanamine (100 mg, 0.31 mmol, 1.00 equiv) and <strong>[75893-75-3]6-cyclopropylpyridine-3-carboxylic acid</strong> (60.7 mg, 0.37 mmol, 1.20 equiv) were dissolved in N,N-dimethylformamide (2 mL), to which were added HATU (176.9 mg, 0.47 mmol, 1.50 equiv) and DIEA (120.3 mg, 0.93 mmol, 3.00 equiv) in sequence at room temperature. The resulting solution was stirred for 16 h at room temperature. When the reaction was done, it was quenched by the addition of 5 mL water and the mixture was extracted with dichloromethane (3*10 mL). The organic layers were combined, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by prep-HPLC using the following conditions: column, X Bridge C18, 19*150 mm, 5 um; mobile phase, acetonitrile in water (with 0.05% TFA), 30% to 70% gradient in 10 min; detector, UV, 254 nm. 6-cyclopropyl-N-([2-fluoro-4-[2-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]phenyl]methyl)pyridine-3-carboxamide (20 mg, 13%) was obtained as white solid. HPLC: 97.7% purity. MS: m/z=468.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6): 6 13.39 (br s, 1H), 9.20-9.17 (m, 1H), 8.91 (d, J=2.0 Hz, 1H), 8.44 (s, 1H), 8.29-8.20 (m, 2H), 8.14-8.11 (m, 3H), 7.56-7.52 (m, 2H), 7.42 (d, J=8.0 Hz, 1H), 4.60 (s, 2H), 3.94 (s, 3H), 2.33-2.15 (m, 1H), 1.05-1.01 (m, 4H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
87% | With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20.0℃; for 1.0h; | 5-[(2R,3R)-3-amino-2-methylpiperidin-1-yl]-3-[4-(oxan-4-yloxy)phenyl]amino}pyrazine-2- carbonitrile (102.8 mg, 0.25 mmol) was dissolved in DMF (4 mL), <strong>[75893-75-3]6-cyclopropylnicotinic acid</strong> (62 mg, 0.38 mmol), DIPEA (0.2 mL, 1.26 mmol) and PyBOP (196 mg, 0.38 mmol) were added. The mixture was stirred at room temperature 1 h. Water and DCM were added and the mixture was extracted with DCM. The organic phase was dried over Na2SO4, filtered and evaporated to give a crude which was purified by silica flash chromatography with 50% to 100% ethyl acetate in cyclohexane to afford N-[(2R,3R)-1-(5-cyano-6-[4-(oxan-4-yloxy)phenyl]amino}pyrazin-2- yl)-2-methylpiperidin-3-yl]-6-cyclopropylpyridine-3-carboxamide (120.7 mg, 87% yield) as a yellow solid. MS found for C31H35N7O3 as (M+H)+ 554.0. |
[ 1970-80-5 ]
(2,2-Bipyridine)-5-carboxylic acid
Similarity: 0.90
[ 1970-81-6 ]
[3,3'-Bipyridine]-5-carboxylic acid
Similarity: 0.83
[ 1970-80-5 ]
(2,2-Bipyridine)-5-carboxylic acid
Similarity: 0.90
[ 1970-81-6 ]
[3,3'-Bipyridine]-5-carboxylic acid
Similarity: 0.83